Medicinal product discount agreements, open house
Original notice title
Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren
Opportunity Score
Why this score?
Opportunity
65 / 100
Complexity
60 / 100
Risk factors
No minimum or estimated volume of sales; revenue depends on actual prescriptions and market share.
If exclusive discount agreements for the same substances are concluded via EU-wide procedures, the open-house contracts...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Supplies contract
- 3 lots
- Duration until Aug 2027
- Non-exclusive discount agreements for pharmaceutical products (23 lots) as per §130a Abs.8 SGB V.
- Supply of specific active substances listed in each lot.
Show full summary
Open-house procedure by IKK classic for non-exclusive pharmaceutical discount agreements under §130a Abs.8 SGB V. 23 lots covering various active substances. Procedure open to all qualified pharmaceutical entrepreneurs. No electronic submission; submissions via email or post. Rolling entry possible until 2027-07-05. Estimated contract value not provided. Award criteria not specified (meeting conditions required). Procurement documents available online but not analyzed.
Risks
No minimum or estimated volume of sales; revenue depends on actual prescriptions and market share.
If exclusive discount agreements for the same substances are concluded via EU-wide procedures, the open-house contracts...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Bidder must be a pharmaceutical entrepreneur as defined in §4 Abs.18 AMG (or consortium of such).
Administrative
- Submission of signed contract, declarations, and required documents by the applicable deadline.
- No electronic submission allowed; submissions via email ([email protected]) or post.
Requirements may be incomplete.
Buyer
Lots (23)
LOT-0001
Abatacept; ATC L04AA24
Supply of Abatacept (ATC L04AA24) for non-exclusive discount agreement. Performance in DE (Saxony).
Location
Duration
Category
Deadline
Award details
Abatacept
ATC-Code: L04AA24
Value note
Show original TED data
Original lot title
Abatacept; ATC-Code: L04AA24
Original TED description
Abatacept; ATC-Code: L04AA24
LOT-0002
Atovaquon; ATC P01AX06
Supply of Atovaquone (ATC P01AX06). Performance in DE.
Location
Duration
Category
Deadline
Award details
Atovaquon
ATC-Code: P01AX06
Value note
Show original TED data
Original lot title
Atovaquon; ATC-Code: P01AX06
Original TED description
Atovaquon; ATC-Code: P01AX06
LOT-0003
Beclometason und Formoterol; Dosieraerosol 100/6µg; ATC R03AK08
Supply of Beclometasone/Formoterol inhaler 100/6µg. Performance in DE.
Location
Duration
Category
Deadline
Award details
Beclometason und Formoterol
Dosieraerosol
100/6µg
ATC-Code: R03AK08
Value note
Show original TED data
Original lot title
Beclometason und Formoterol; Dosieraerosol; 100/6µg; ATC-Code: R03AK08
Original TED description
Beclometason und Formoterol; Dosieraerosol; 100/6µg; ATC-Code: R03AK08
LOT-0004
Beclometason und Formoterol; Dosieraerosol 200/6µg; ATC-Code: R03AK08
Beclometason und Formoterol; Dosieraerosol 200/6µg; ATC-Code: R03AK08
Location
Duration
Category
Award details
Beclometason und Formoterol
Dosieraerosol 200/6µg
ATC-Code: R03AK08
LOT-0005
Beclometason und Formoterol; Inhalationspulver, Inhalat; ATC-Code: R03AK08
Beclometason und Formoterol; Inhalationspulver, Inhalat; ATC-Code: R03AK08
Location
Duration
Category
Award details
Beclometason und Formoterol
Inhalationspulver, Inhalat
ATC-Code: R03AK08
LOT-0006
Betain; ATC-Code: A16AA06
Betain; ATC-Code: A16AA06
Location
Duration
Category
Award details
Betain
ATC-Code: A16AA06
LOT-0007
Brinzolamid und Brimonidin; ATC-Code: S01EC24 (ADV); S01EC54 (WHO)
Brinzolamid und Brimonidin; ATC-Code: S01EC24 (ADV); S01EC54 (WHO)
Location
Duration
Category
Award details
Brinzolamid und Brimonidin
ATC-Code: S01EC24 (ADV)
S01EC54 (WHO)
LOT-0008
Certolizumabpegol; ATC-Code: L04AB05
Certolizumabpegol; ATC-Code: L04AB05
Location
Duration
Category
Award details
Certolizumabpegol
ATC-Code: L04AB05
LOT-0009
Colesevelam; ATC-Code: C10AC04
Colesevelam; ATC-Code: C10AC04
Location
Duration
Category
Award details
Colesevelam
ATC-Code: C10AC04
LOT-0010
Etravirin; ATC-Code: J05AG04
Etravirin; ATC-Code: J05AG04
Location
Duration
Category
Award details
Etravirin
ATC-Code: J05AG04
LOT-0011
Immunglobuline intravasal; ATC-Code: J06BA02
Immunglobuline intravasal; ATC-Code: J06BA02
Location
Duration
Category
Award details
Immunglobuline intravasal
ATC-Code: J06BA02
LOT-0012
Immunglobuline, normal human, zur extravasalen Anwendung; ATC-Code: J06BA01
Immunglobuline, normal human, zur extravasalen Anwendung; ATC-Code: J06BA01
Location
Duration
Category
Award details
Immunglobuline, normal human, zur extravasalen Anwendung
ATC-Code: J06BA01
LOT-0013
Melatonin, 1 mg oder 5 mg pro Retardtablette; Indikation: Behandlung von Schlafstörungen (Insomnie) bei Kindern und Jugendlichen im Alter von 2-18 Jahren mit Autismus-Spektrum-Störung (ASS) und/oder Smith-Magenis-Syndrom, wenn Schlafhygienemaßnahmen unzureichend waren.; ATC-Code: N05CH01
Melatonin, 1 mg oder 5 mg pro Retardtablette; Indikation: Behandlung von Schlafstörungen (Insomnie) bei Kindern und Jugendlichen im Alter von 2-18 Jahren mit Autismus-Spektrum-Störung (ASS) und/oder Smith-Magenis-Syndrom, wenn Schlafhygienemaßnahmen unzureichend waren.; ATC-Code: N05CH01
Location
Duration
Category
Award details
Melatonin, 1 mg oder 5 mg pro Retardtablette
Indikation: Behandlung von Schlafstörungen (Insomnie) bei Kindern und Jugendlichen im Alter von 2-18 Jahren mit Autismus-Spektrum-Störung (ASS) und/oder Smith-Magenis-Syndrom, wenn Schlafhygienemaßnahmen unzureichend waren.
ATC-Code: N05CH01
LOT-0014
Omalizumab; ATC-Code: R03DX05
Omalizumab; ATC-Code: R03DX05
Location
Duration
Category
Award details
Omalizumab
ATC-Code: R03DX05
LOT-0015
Palonosetron; Weichkapseln; ATC-Code: A04AA05
Palonosetron; Weichkapseln; ATC-Code: A04AA05
Location
Duration
Category
Award details
Palonosetron
Weichkapseln
ATC-Code: A04AA05
LOT-0016
Ponesimod; ATC-Code: L04AE04
Ponesimod; ATC-Code: L04AE04
Location
Duration
Category
Award details
Ponesimod
ATC-Code: L04AE04
LOT-0017
Relugolix; ATC-Code: L02BX04
Relugolix; ATC-Code: L02BX04
Location
Duration
Category
Award details
Relugolix
ATC-Code: L02BX04
LOT-0018
Sumatriptan, Injektionslösung, Injektionslösung in einem Fertigpen, Nasenspray; ATC-Code: N02CC01
Sumatriptan, Injektionslösung, Injektionslösung in einem Fertigpen, Nasenspray; ATC-Code: N02CC01
Location
Duration
Category
Award details
Sumatriptan, Injektionslösung, Injektionslösung in einem Fertigpen, Nasenspray
ATC-Code: N02CC01
LOT-0019
Tacrolimus 0,03 % Salbe; ATC-Code: D11AH01
Tacrolimus 0,03 % Salbe; ATC-Code: D11AH01
Location
Duration
Category
Award details
Tacrolimus 0,03 % Salbe
ATC-Code: D11AH01
LOT-0020
Tiotropiumbromid; Inhalationslösung; ATC-Code: R03BB04
Tiotropiumbromid; Inhalationslösung; ATC-Code: R03BB04
Location
Duration
Category
Award details
Tiotropiumbromid
Inhalationslösung
ATC-Code: R03BB04
LOT-0021
Trifluridin, Kombinationen; ATC-Code: L01BC59
Trifluridin, Kombinationen; ATC-Code: L01BC59
Location
Duration
Category
Award details
Trifluridin, Kombinationen
ATC-Code: L01BC59
LOT-0022
Eltrombopag; ohne die Indikation schwere aplastische Anämie, es sei denn, der pharmazeutische Unternehmer besitzt hierfür Patentrechte oder eine lizenzbedingte Legitimation; ATC-Code: B02BX05
Eltrombopag; ohne die Indikation schwere aplastische Anämie, es sei denn, der pharmazeutische Unternehmer besitzt hierfür Patentrechte oder eine lizenzbedingte Legitimation; ATC-Code: B02BX05
Location
Duration
Category
Award details
Eltrombopag
ohne die Indikation schwere aplastische Anämie, es sei denn, der pharmazeutische Unternehmer besitzt hierfür Patentrechte oder eine lizenzbedingte Legitimation
ATC-Code: B02BX05
LOT-0023
Dexamethason; Implantat; ATC-Code: S01BA01
Dexamethason; Implantat; ATC-Code: S01BA01
Location
Duration
Category
Award details
Dexamethason
Implantat
ATC-Code: S01BA01
Procurement Details
- Publication date
- 19 Aug 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 544757-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Why this score?
Opportunity
65 / 100
Complexity
60 / 100
Risk factors
No minimum or estimated volume of sales; revenue depends on actual prescriptions and market share.
If exclusive discount agreements for the same substances are concluded via EU-wide procedures, the open-house contracts...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications